Placement of Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins

Status unconfirmed · Not applicable

Conditions studied: Hemodialysis

In brief

Balloon angioplasty is used to open up a narrowing that forms in hemodialysis fistula. Two areas of particular problems are the terminal portion of the cephalic vein near the shoulder and the central veins in the chest. Although angioplasty is standard of care the treated narrowed segments of vein mostly renarrow within 3 months requiring retreatment to keep your dialysis access functional. Recently there has been introduction of a new technology called a covered stent graft. Initial studies suggest that placing this device across the area of narrowing leads to dialysis access staying open longer and needing less angioplasty treatments. This study is designed to compare angioplasty (standard of care) versus using a covered stent graft. The investigators will then look at the dialysis records and future fistulograms to see if there is decreased flow through the fistula at 3, 6 and 12 months after the initial procedure.

Key facts

Study ID

NCT01271881

Run by

American Access Care

People needed

140

Starts

2010-10-01

Last updated by the study team

2011-01-07

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hemodialysis patient with a mature forearm or upper arm access that was created > 2 months before enrollment in study.
• The patient is ≥ 18 years of age.
• The patient has a reasonable expectation of remaining on hemodialysis for 12 months.
• The patient or his/her legal guardian understands the study and is willing and able to comply with follow-up requirements.
• The patient or his/her legal guardian is willing to provide informed consent.
• The patient has lesions that meet the angiographic inclusion / exclusion criteria and induce clinical, hemodynamic or functional abnormality.

You may not qualify if…

• The patient has a known or suspected systemic infection.
• The patient has a known or suspected infection of the hemodialysis access and / or bacteremia.
• The patient is currently taking maintenance immunosuppressant medication such as rapamycin, mycophenolate or mycophenolic acid, prednisone (>10 mg per day), cyclosporine, tacrolimus, or cyclophosphamide.
• The patient has known bleeding disorder (e.g., hemophilia or von Willebrand's disease).
• The patient has known sensitivity to heparin.
• The patient is scheduled for a live donor kidney transplant.
• The patient is enrolled in another investigational study or another access maintenance trial
• The patient has comorbid conditions that may limit their ability to comply with the follow-up requirements
• Life expectancy is ≤ 24 months.
• The patient has an untreatable allergy to radiographic contrast material.
• The patient is pregnant.
• In the opinion of the operating physician, the patient's hemodialysis access circuit is unsuitable for endovascular treatment.
• The patient's access is planned to be abandoned within 1 year.
• The patient has indwelling catheters (dialysis, pacemakers, ports).
• The patient has a central vein stent that would lead to jailing of the internal jugular vein.
• The patient experiences angioplasty-induced venous rupture.
• The patient has a flow limiting dissection after angioplasty.
• The patient's hemodialysis access is thrombosed.

Where it is running

• American Access Care of Queens — Flushing, New York, United States (enrolling)
• American Access Care of Bronx — The Bronx, New York, United States (enrolling)
• Access Care Physicians of New York — White Plains, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.